Gregory N. Dietsch
Directeur Technique/Scientifique/R&D chez VentiRx Pharmaceuticals, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Steven Gillis | M | 71 |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | - |
Kent Snyder | M | 70 |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | - |
Patrick Heron | M | 53 |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | - |
Ron Laufer | M | 57 |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | - |
Tressa D. Randall | F | - |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | - |
Anthony L. Kiorpes | M | - |
American Board of Toxicology
| - |
Michael L. Dourson | M | - |
American Board of Toxicology
| - |
Tom Swallow | M | - |
VentiRx Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology VentiRx Pharmaceuticals, Inc. develops and commercializes novel medicines for the treatment of cancer, respiratory, and inflammatory diseases. It focuses on the development of novel small molecule product candidates targeting toll-like receptor 8 for applications in oncology, allergy, autoimmune, and inflammatory diseases. The company was founded by Michael J. Kamdar and Robert Hershberg on June 12, 2006 and is headquartered in Seattle, WA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 8 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Gregory N. Dietsch
- Réseau Personnel